Regen Biopharma Inc Net Income per Employee (RGBP), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Regen Biopharma Inc   (RGBP)
 

Regen Biopharma Inc Net Income per Employee

RGBP's Quarterly Results, Trends, Rankings, Statistics
Regen Biopharma Inc recorded a cumulative net loss of $-2 million during 12 month ending in the third quarter 2026.
The Healthcare sector has seen employees of 151 other companies achieving higher income per employee. While Regen Biopharma Inc 's total ranking has deteriorated compared to the previous quarter from 3452 to 3487.


What is Income per Employee Ratio?






RGBP Net Income per Employee (Jun 30 2026)
III. Quarter
(Mar 31 2026)
II. Quarter
(Dec 31 2025)
I. Quarter
(Sep 30 2025)
IV. Quarter
(Jun 30 2025)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -668,365 -511,534 -747,452 -596,629 -260,315
RGBP's Total Ranking # 3487 # 3452 # 2685 # 3232 # 2625
Seq. Net Income Change - - - - -


RGBP Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 152
Healthcare Sector # 463
Overall Market # 3487

Net Income per Employee Statistics
High Average Low
$ 20,749,122 $ -835,484 $ -24,521,442
(Mar 31 2023)   (Mar 31 2022)







Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-08-18T07:46:10+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.